Abstract 4348: A translational pharmacokinetic-pharmacodynamic (PKPD) modeling framework of novel, highly selective, next-generation allosteric cyclin-dependent kinase 2 (CDK2) inhibitors
Year: 2025
Type: conference-abstract
Source: Cancer Research
Institutions: Bayer (Germany), Bayer (Switzerland), Bayer (United States)
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4409627186